Condition category
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting
Publication status
Results overdue

Plain English Summary

Not provided at time of registration

Trial website

Contact information



Primary contact

Dr Lars Vedin


Contact details

Floragatan 13
SE-114 75
+46 (0)8 5064 5751

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title


Study hypothesis

To assess the fasibility of manganese chloride tetrahydrate (CMC-001©) as a contrast medium in liver Magnetic Resonance Imaging (MRI) scanning.

The secondary objectives are to further evaluate the safety and tolerability of CMC-001© in patients.

Ethics approval

Approval received from the official board of the UMC St Radboud of Nijmegen on the 25th May 2004 (ref: SE/AMO 0339).

Study design

The study was open and non-randomised, with each patient being his own control. The evaluation of the MR images was performed by two independent observers.

Primary study design


Secondary study design

Non randomised controlled trial

Trial setting


Trial type


Patient information sheet


Verified liver metastases


CMC-100© is a contrast agent taken by the oral route intended for use in MRI scanning of the liver, gallbladder and surrounding tissues. In this, the first phase II trial, the intention was to find out how well liver metastases could be visualised in contrast to the surrounding healthy liver tissue. To this end a MRI image taken before contrast was compared to a MRI picture taken three hours after contrast by two independent observers. Some of the patients also had a third MRI 24 hours after contrast in order to see if the gallbladder could be visualised. 48 hours after contrast the patients were called on the phone out of safety reasons in order to find out if they had experienced any Adverse Events (AEs).

No interventions besides the MRI and a screen of blood samples for safety analyses and a special blood sample for manganese alalyse were done.

Intervention type



Phase II

Drug names

Manganese chloride tetrahydrate (CMC-001©) contrasting agent

Primary outcome measure

The primary endpoint was efficacy. The MR image before contrast was compared to the MR image three hours after contrast and in a small number of patients also a MR image 24 hours after contrast.

Secondary outcome measures

Secondary parameters was the safety of the contrast. AEs were recorded as long as the patients were staying at the clinic and were called 48 hours after contrast and interviewed about any untoward experiences.

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Signed written informed consent after oral and written information about the study has been given by the investigator
2. Patients with liver metastases verified with other imaging techniques
3. Men or women over 18 years old
4. The patient is conscious and co-operative

Participant type


Age group




Target number of participants


Participant exclusion criteria

1. Clinically relevant medical history or abnormal physical findings which could interfere with the safety or objectives of the study as judged by the investigator
2. Clinically relevant haematology, clinical chemistry, serology and urine chemistry abnormalities. This is based on the judgement of the treatment physicians
3. Use of any prescribed, over-the-counter or herbal medication one week prior to entering the study, which might interfere with the safety or the objectives of this study
4. Use of all types of products containing manganese, vitamin D or products containing amino acids during the examination day until after the 24-hour examination
5. Allergy to any of the study product compounds
6. Drug or alcohol abuse by asking the patient at screening
7. Patients who are deemed to be unsuitable for any other reason in the opinion of the investigator
8. Participation in another clinical study concerning another contrast preparation within the last three months or seven days after this study
9. Previous inclusion in this study
10. Pregnancy
11. The patient is scheduled to receive iodinated contrast medium intravascular within three days after this study
12. The patient is being investigated on an emergency basis
13. The patient has newly discovered unstable diabetes or undergoes haemodialysis or peritoneal dialysis
14. The patient has a concurrent illness that may influence the renal function or has undergone kidney transplantation
15. The patient has a concurrent illness in the Gastrointestinal (GI) tract or clinically manifest icterus
16. Known Human Immunodeficiency Virus (HIV) infection or Acquired Immune Deficiency Syndrome (AIDS)
17. Hepatitis
18. The patient has uncompensated cardiac failure (cardiac failure New York Heart Association [NYHA] grade four)
19. A patient may be excluded during the trial based on the clinical judgement of the clinician or the radiologist

Recruitment start date


Recruitment end date



Countries of recruitment


Trial participating centre

Floragatan 13
SE-114 75

Sponsor information


Copenhagen Malmö Contrast AB (CMC Contrast AB) (Sweden)

Sponsor details

c/o Lars Vedin AB
Floragatan 13
SE-114 75
+46 (0)8 5064 5751

Sponsor type




Funder type


Funder name

Copenhagen Malmö Contrast AB (CMC Contrast AB) (Sweden)

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Basic results (scientific)

Publication list

Publication citations

Additional files

Editorial Notes